tbuckley/cabot-search huggingface dataset:
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease (vol 374, pg 1134, 2016)
Authors: Nathan O. Stitziel, Kathleen E. Stirrups, Nicholas G. D. Masca, Jeanette Erdmann, Paola G. Ferrario, Inke R. Koenig, Peter E. Weeke, Thomas R. Webb, Paul L. Auer, Ursula M. Schick, Yingchang Lu, He Zhang, Marie-Pierre Dube, Anuj Goel, Martin Farrall, Gina M. Peloso, Hong-Hee Won, Ron Do, Erik van Iperen, Stavroula Kanoni, Jochen Kruppa, Anubha Mahajan, Robert A. Scott, Christina Willenborg, Peter S. Braund, Julian C. van Capelleveen, Alex S. F. Doney, Louise A. Donnelly, Rosanna Asselta, Piera A. Merlini, Stefano Duga, Nicola Marziliano, Josh C. Denny, Christian M. Shaffer, Nour Eddine El-Mokhtari, Andre Franke, Omri Gottesman, Stefanie Heilmann, Christian Hengstenberg, Per Hoffmann, Oddgeir L. Holmen, Kristian Hveem, Jan-Hakan Jansson, Karl-Heinz Joeckel, Thorsten Kessler, Jennifer Kriebel, Karl L. Laugwitz, Eirini Marouli, Nicola Martinelli, Mark I. McCarthy, Natalie R. van Zuydam, Christa Meisinger, Tonu Esko, Evelin Mihailov, Stefan A. Escher, Maris Alver, Susanne Moebus, Andrew D. Morris, Martina Muller-Nurasyid, Majid Nikpay, Oliviero Olivieri, Louis-Philippe Lemieux Perreault, Alaa AlQarawi, Neil R. Robertson, Karen O. Akinsanya, Dermot F. Reilly, Thomas F. Vogt, Wu Yin, Folkert W. Asselbergs, Charles Kooperberg, Rebecca D. Jackson, Eli Stahl, Konstantin Strauch, Tibor V. Varga, Melanie Waldenberger, Lingyao Zeng, Aldi T. Kraja, Chunyu Liu, Georg B. Ehret, Christopher Newton-Cheh, Daniel I. Chasman, Rajiv Chowdhury, Marco Ferrario, Ian Ford, J. Wouter Jukema, Frank Kee, Kari Kuulasmaa, Borge G. Nordestgaard, Markus Perola, Danish Saleheen, Naveed Sattar, Praveen Surendran, David Tregouet, Robin Young, Joanna M. M. Howson, Adam S. Butterworth, John Danesh, Diego Ardissino, Erwin P. Bottinger, Raimund Erbel, Paul W. Franks, Domenico Girelli, Alistair S. Hall, G. Kees Hovingh, Adnan Kastrati, Wolfgang Lieb, Thomas Meitinger, William E. Kraus, Svati H. Shah, Ruth McPherson, Marju Orho-Melander, Olle Melander, Andres Metspalu, Colin N. A. Palmer, Annette Peters, Daniel J. Rader, Muredach P. Reilly, Ruth J. F. Loos, Alex P. Reiner, Dan M. Roden, Jean-Claude Tardif, John R. Thompson, Nicholas J. Wareham, Hugh Watkins, Cristen J. Willer, Sekar Kathiresan, Panos Deloukas, Nilesh J. Samani, Heribert Schunkert
Journal: New England Journal of Medicine (2016)
Governing multisectoral action for health in low- and middle-income countries
Authors: Kumanan Rasanathan, Sara Bennett, Vincent Atkins, Robert Beschel, Gabriel Carrasquilla, Jodi Charles, Rajib Dasgupta, Kirk Emerson, Douglas Glandon, Churnrurtai Kanchanachitra, Pete Kingsley, Don Matheson, Rees Murithi Mbabu, Charles Mwansambo, Michael Myers, Jeremias Paul, Thulisile Radebe, James Smith, Orielle Solar, Agnès Soucat, Aloysius Ssennyonjo, Matthias Wismar, Shehla Zaidi
Journal: PLoS Medicine (2017)

The focus of the health sector in most countries remains almost exclusively on health care services, and the potential of multisectoral collaboration remains untapped in many low-and middle-income countries.• Different sectors have different contributions to make towards solving specific health problems.In each case, the profile, interests, incentives, and relationships of key individuals and sectors must be mapped and analysed to inform the design of approaches and systems to tackle a shared problem.• Collaborative and distributed leadership is key for effective governance of multisectoral action, with a need to build leadership capacity across sectors and levels of government and cultivate champions in different sectors who can agree on common objectives.• Important ways forward to support countries to take a multisectoral approach for health include ensuring that the universal health coverage agenda addresses the capacity of the health sector to work with other sectors, learning from multisectoral efforts that do not involve the health sector, improving the capacity of global institutions to support countries in undertaking multisectoral action, and developing a clear implementation research agenda for multisectoral action for health.
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer
Authors: Kari Chansky, Frank C. Detterbeck, Andrew G. Nicholson, Valerie W. Rusch, Eric Vallières, Patti Groome, Catherine Kennedy, Mark Krasnik, Michael Peake, Lynn Shemanski, Vanessa Bolejack, John J. Crowley, Hisao Asamura, Ramón Rami-Porta, Peter Goldstraw, Ramón Rami-Porta, Hisao Asamura, David Ball, David G. Beer, Ricardo Beyruti, Vanessa Bolejack, Kari Chansky, John Crowley, Frank Detterbeck, Wilfried Ernst Erich Eberhardt, John Edwards, Françoise Galateau-Sallé, Dorothy Giroux, Fergus Gleeson, Patti Groome, James Huang, Catherine Kennedy, Jhingook Kim, Young Tae Kim, Laura Kingsbury, Haruhiko Kondo, Mark Krasnik, Kaoru Kubota, Antoon Lerut, Gustavo Lyons, Mirella Marino, Edith M. Marom, Jan van Meerbeeck, Alan Mitchell, Takashi Nakano, Andrew G. Nicholson, Anna Nowak, Michael Peake, Thomas Rice, Kenneth Rosenzweig, Enrico Ruffini, Valerie Rusch, Nagahiro Saijo, Paul Van Schil, Jean-Paul Sculier, Lynn Shemanski, Kelly Stratton, Kenji Suzuki, Yuji Tachimori, Charles F. Thomas, William Travis, Ming S. Tsao, Andrew Turrisi, Johan Vansteenkiste, Hirokazu Watanabe, Yi-Long Wu, Paul Baas, Jeremy Erasmus, Seiki Hasegawa, Kouki Inai, Kemp Kernstine, Hedy Kindler, Lee Krug, Kristiaan Nackaerts, Harvey Pass, David Rice, Conrad Falkson, Pier Luigi Filosso, Giuseppe Giaccone, Kazuya Kondo, Marco Lucchi, Meinoshin Okumura, Eugene Blackstone, F. Abad Cavaco, E. Ansótegui Barrera, J. Abal Arca, I. Parente Lamelas, A. Arnau Obrer, R. Guijarro Jorge, D. Ball, G.K. Bascom, A. I. Blanco Orozco, M. A. González Castro, M.G. Blum, D. Chimondeguy, V. Cvijanovic, S. Defranchi, B. de Olaiz Navarro, I. Escobar Campuzano, I. Macía Vidueira, E. Fernández Araujo, F. Andreo García, K.M. Fong, G. Francisco Corral, S. Cerezo González, J. Freixinet Gilart, L. García Arangüena, S. García Barajas, P. Girard, T. Goksel, M. T. González Budiño, G. González Casaurrán, J. A. Gullón Blanco, J. Hernández Hernández, H. Hernández Rodríguez, J. Herrero Collantes, M. Iglesias Heras, J. M. Izquierdo Elena, E. Jakobsen, S. Kostas, P. León Atance, A. Núñez Ares, M. Liao, M. Losanovscky, G. Lyons, R. Magaroles, L. De Esteban Júlvez, M. Mariñán Gorospe, B. McCaughan, C. Kennedy, R. Melchor Íñiguez, L. Miravet Sorribes, S. Naranjo Gozalo, C. Álvarez de Arriba, M. Núñez Delgado, J. Padilla Alarcón, J. C. Peñalver Cuesta, J.S. Park, H. Pass, M. J. Pavón Fernández, M. Rosenberg, E. Ruffini, V. Rusch, J. Sánchez de Cos Escuín, A. Saura Vinuesa, M. Serra Mitjans, T.E. Strand, D. Subotic, S. Swisher, R. Terra, C. Thomas, K. Tournoy, P. Van Schil, M. Velasquez, Y.L. Wu, K. Yokoi
Journal: Journal of Thoracic Oncology (2017)
IgE sensitization in relation to preschool eczema and filaggrin mutation
Authors: Emma Kristin Johansson, Anna Bergström, Inger Kull, Tomas Lind, Cilla Söderhäll, Marianne van Hage, Magnus Wickman, Natalia Ballardini, Carl-Fredrik Wahlgren
Journal: Journal of Allergy and Clinical Immunology (2017)
Consequences of Sibling Death
Authors: James M. Bolton, Rae Spiwak, Jitender Sareen
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: a multicenter international experience
Authors: Michel Kahaleh, Jean-Michel Gonzalez, Ming-ming Xu, Iman Andalib, Monica Gaidhane, Amy Tyberg, Monica Saumoy, Alberto Jose Baptista Marchena, Marc Barthet
Journal: Endoscopy (2018)

Abstract Background Gastroparesis is a difficult-to-treat motility disorder with a poor response to medical therapy. Gastric peroral endoscopic pyloromyotomy (G-POEM) has been offered as a novel therapy in the treatment of refractory gastroparesis. We present a multicenter case series of our experience with G-POEM. Methods This is an international multicenter case series of patients who underwent G-POEM for the treatment of gastroparesis. The severity of gastroparesis was assessed by delayed gastric emptying scintigraphy (GES) and an elevated gastroparesis cardinal symptoms index (GCSI). Patients then underwent G-POEM using the submucosal tunneling technique. The primary endpoint was improvement in the GCSI score and improvement in gastric emptying on repeat scintigraphy. Secondary endpoints were technical success, complication rate, procedure duration, and length of hospital stay post-procedure. Results G-POEM was technically successful in all 33 patients. Symptomatic improvement was seen in 28/33 patients (85 %), with a decrease in symptom score by GCSI from 3.3 to 0.8 at follow-up (P &lt; 0.001). The mean procedure duration was 77.6 minutes (37 – 255 minutes). Mean GES improved significantly from 222.4 minutes to 143.16 minutes (P &lt; 0.001). Complications were minimal and included bleeding (n = 1) and an ulcer (n = 1) treated conservatively. The mean length of hospital stay post-procedure was 5.4 days (1 – 14 days). The mean follow-up duration was 11.5 months (2 – 31 months). Conclusion G-POEM is a technically feasible, safe, and successful procedure for the treatment of refractory gastroparesis. A further multicenter comparative study should be performed to compare this technique to laparoscopic pyloromyotomy.
P06.06 A mutation-specific vaccine for Histone-3 K27M-mutated gliomas
Authors: K. Ochs, M. Ott, T. Bunse, F. Sahm, L. Bunse, M. Keil, K. Deumelandt, J. Sonner, A. von Deimling, W. Wick, M. Platten
Journal: Neuro-Oncology (2017)

Contrary to the assumption that brain tumors are hardly immunogenic, immunotherapeutic approaches such as antigen-specific vaccines have become increasingly relevant in clinical trials for malignant gliomas. For instance, a point mutation in the gene for isocitrate dehydrogenase type 1 frequently present in adult diffuse gliomas has been shown to result in an immunogenic epitope currently targeted by an experimental vaccine in clinical trials. Another example of a recently discovered oncogenic mutation occurring especially in pediatric high grade midline gliomas is a point mutation in the histone-3 gene (H3F3A). Here, an amino acid exchange from lysine to methionine at position 27 (K27M) leads to reduction of H3.3 K27 trimethylation resulting in a distinct global methylation and gene expression pattern. Here, we analyzed the immunogenicity of H3.3 K27M and its relevance for a mutation-specific vaccination approach. Vaccination of major histocompatibility complex (MHC)-humanized (A2.DR1) mice with a H3.3 K27M-covering 27mer peptide induced CD8-driven mutation-specific immune responses. Using a human leukocyte antigen (HLA) epitope prediction algorithm, a mutation-containing 10mer peptide sequence with a strong binding affinity to HLA-A*02 was identified and subsequently confirmed as immunogenic class I neoepitope in vivo. Consequently, K27M peptide vaccination of A2.DR1 mice effectively inhibited growth of pre-established H3.3 K27M-expressing syngeneic tumors. Of clinical importance, mutation-specific cytotoxic T cells could be detected in the peripheral blood of patients with H3.3 K27M-mutated gliomas supporting the significance of K27M as immunogenic glioma neoepitope. Thus, our data provide evidence for a further clinical development of a vaccine targeting K27M for patients with H3.3 K27M-mutated gliomas.
P18.10 Impact of glioblastoma multiforme (GBM) on patients’ quality of life (QoL)
Authors: K. Byrne, J. Waller, J. Piercy, J. Shaw, H. Dastani
Journal: Neuro-Oncology (2017)

Objective: To assess the QoL reported by GBM patients and their caregivers METHODOLOGY: Real-world data were collected through a cross-sectional survey administered to physicians, patients, and caregivers in France, Germany, and the UK between May and July 2016. Physicians confirmed diagnosis and assessed patients as having progressed, being stable, or responding to treatment. Patient-reported outcomes (PROs) were measured using the 3-level EQ-5D as well as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and brain cancer-specific module (QLQ-BN20). For patients who could not complete the EQ-5D, proxy assessments were obtained from caregivers. Summary statistics were reported and differences were assessed using pairwise t tests. Results: A total of 313 GBM patients completed the PRO measures, while 203 caregivers provided a proxy EQ-5D assessment. Patient QoL was poor as indicated by a mean (SD) EQ-5D index score of 0.51 (0.38). Significant differences were observed among patient groups defined according to progression. Those whose disease had progressed had a mean (SD) index score of 0.26 (0.38) compared with 0.53 (0.37 p<0.001) for those with stable disease, and with 0.61 (0.34 p<0.001) for those with treatment-responsive disease. Proxy EQ-5D results from caregivers were qualitatively similar - progressed vs. stable (0.38 (0.37) vs. 0.43 (0.37) (p=0.178)), and progressed vs. treatment-responsive (0.38 (0.37) vs. 0.47 (0.37) (p=0.178)). Patient health status, indicated by the EORTC QLQ-C30 global health scale, was poor with a mean (SD) score of 44.0 (20.9). Patients with progressed disease reported a health status mean (SD) score of 35.3 (19.5), worse than stable patients 44.9 (21.6) (p<0.001) and worse than treatment-responsive patients 47.6 (22.6) (p<0.001). Similar differences were observed with regard to physical and cognitive functioning. For physical function mean (SD) scores for progressed were 47.8 (22.6) compared to stable 58.6 (24.8) (p<0.001) and to treatment responsive 65.4 (23.4) (p<0.001). With cognitive function mean (SD) scores were progressed 43.6 (28.2) compared to stable 54.7 (24.8) (p<0.001) and again to treatment responsive 56.2 (25.1) (p<0.001). Symptom burden, as measured using the EORTC QLQ-BN20, was also pronounced. Mean (SD) scores for scales measuring communication deficit, motor dysfunction, and visual disorder were 34.6 (27.3), 30.9 (27.1), and 25.2 (26.5), respectively. Overall, patients exhibited unease about their condition, with a mean (SD) score for future uncertainty of 59.1 (25.7). CONCLUSION: Patients with progressive GBM report worse QoL than those with stable disease or those who respond to treatment. These findings suggest a need for effective and tolerable treatments that can conserve patient QoL.
P09.06 Bevacizumab in recurrent malignant glioma, a single institution experience
Authors: J. Cunha, M. Almeida
Journal: Neuro-Oncology (2017)

Background: Treatment options of recurrent malignant gliomas are limited and with a poor survival benefit. In the inevitably recurrent setting of this disease, no chemotherapy regimen has demonstrated its clinical benefit giving the opportunity to identify alternative therapies such as antiangiogenic molecules. Materials and methods: The medical data of 49 patients with recurrent malignant gliomas was retrospectively reviewed from June 2013 to November 2015. Patient clinical characteristics, pathologic findings and progression free survival (PFS) was evaluated. Results: 48 patients (median age 62, male 67%) were treated with a regimen including bevacizumab. Thirty six patients had gliobastoma, 10 oligodendroglioma, 1 anaplastic astrocytoma, 1 ependymoma and 1 fibrillary astrocytoma. In most of the cases the disease involved the left frontal lobe. With the exception of two patients, in which the performance status lead to the decision of palliative rathiotherapy, the other patients had the standard of care, this is, primary ressection followed by postoperative chemotherapy. 29 patients (60%) underwent bevacizumab associated with irinothecan in their first relapse, 14 (29%) in their second relapse and 3 (6%) in their third relapse. 24 patients died. The median follow up time was 19.6 months. The median progression free survival (PFS) was 8.6 months. Conclusions: Bevacizumab associated with irinothecan is an effective treatment for recurrent gliobastoma however it is important to collect more data in order to demonstrate that an improved PFS translates in to a overall survival (OS) benefit.
P18.12 Patient-reported outcome measures and health-related quality of life in patients who undergo an intervention for brain metastases: a systematic review
Authors: A. C. DiRisio, E. Nassr, M. Harary, A. Ermakova, M. L. Broekman, R. A. Mekary, T. R. Smith
Journal: Neuro-Oncology (2017)

Introduction: Historically, outcome measures of neurosurgical or radiotherapeutic intervention for brain metastases have focused on overall or progression free survival, but understanding patient-reported outcomes and health-related quality of life has become increasingly important. Rates of brain metastases have risen due to lengthened life expectancies in patients with systemic cancer and better detection with improved imaging modalities. Brain metastases are reported in 20-40% of patients with systemic cancers and are associated with reduced quality of life and shortened life expectancy. A variety of patient-reported outcome measures (PROMs) have been employed to assess the effect of therapy on quality of life in this population. Here, we review all PROMs relevant to patients with brain metastases. Methods: A systematic review of the literature was conducted in accordance with the PRISMA guidelines using PubMed, Embase, and Cochrane databases. Selected studies reported outcomes on brain metastasis patients treated with neurosurgical intervention, whole brain radiation therapy, or stereotactic radiotherapy. Patient-reported data on health related quality of life were extracted from the studies that met the inclusion criteria. A meta-analysis was not performed due to the heterogeneity in health-related quality of life metrics. Results: From our search we identified 2526 articles. We included 177 full text articles after the initial screening. The methods and instruments used to assess health-related quality of life in patients treated for brain metastases were heterogeneous. In addition to the physical effects of the disease itself, the psychological implications of the diagnosis and the neurologic effects of treatment were major contributors to the reduced quality of life in these patients. Conclusion: There is a lack of PROMs specific for brain metastasis patients, yet an understanding of quality of life outcomes in these patients can be useful to clinicians in informing goal-directed care discussions. Therefore, future research on neurosurgical or radiotherapeutic interventions for brain metastasis should focus not only on survival-ship but also on indicators of life quality and patient-reported outcomes. Clinicians should continue to incorporate quality of life outcomes in their discussion with patients about therapeutic options for brain metastases.
Monitoring of Adult T-Cell Leukemia-Lymphoma Cells in Patients Receiving Mogamulizumab, a Humanized Anti-CCR4 Monoclonal Antibody, Using T-Cell Receptor Repertoire Analysis
Authors: Masato Saito, Takashi Ishida, Itaru Urakawa, Toshihiko Ishii, Asahi Ito, Ayako Masaki, Susumu Suzuki, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Takeshi Takahashi, Ryuzo Ueda, Shinsuke Iida
Journal: Blood (2016)
Predictive value of serum <scp>sST</scp>2 in preschool wheezers for development of asthma with high FeNO
Authors: M. E. Ketelaar, K. D. van de Kant, F. N. Dijk, E. M. Klaassen, N. S. Grotenboer, M. C. Nawijn, E. Dompeling, G. H. Koppelman
Journal: Allergy (2017)

Wheezing is common in childhood. However, current prediction models of pediatric asthma have only modest accuracy. Novel biomarkers and definition of subphenotypes may improve asthma prediction. Interleukin-1-receptor-like-1 (IL1RL1 or ST2) is a well-replicated asthma gene and associates with eosinophilia. We investigated whether serum sST2 predicts asthma and asthma with elevated exhaled NO (FeNO), compared to the commonly used Asthma Prediction Index (API). Using logistic regression modeling, we found that serum sST2 levels in 2-3 years-old wheezers do not predict doctors' diagnosed asthma at age 6 years. Instead, sST2 predicts a subphenotype of asthma characterized by increased levels of FeNO, a marker for eosinophilic airway inflammation. Herein, sST2 improved the predictive value of the API (AUC=0.70, 95% CI 0.56-0.84), but had also significant predictive value on its own (AUC=0.65, 95% CI 0.52-0.79). Our study indicates that sST2 in preschool wheezers has predictive value for the development of eosinophilic airway inflammation in asthmatic children at school age.
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review
Authors: Viktor Soukup, Otakar Čapoun, Daniel Cohen, Virginia Hernández, Marek Babjuk, Max Burger, Eva Compérat, Paolo Gontero, Thomas Lam, Steven MacLennan, A. Hugh Mostafid, Joan Palou, Bas W.G. van Rhijn, Morgan Rouprêt, Shahrokh F. Shariat, Richard Sylvester, Yuhong Yuan, Richard Zigeuner
Journal: European Urology (2017)
P14.12 Molecular characteristics of metastatic brain tumor
Authors: Y. Lee, K. Park
Journal: Neuro-Oncology (2017)

BACKGROUND: Purpose of this study was to analyze the molecular characteristics of metastatic brain tumors including lung, colorectal and breast cancer comparing with their molecular characteristics of primary cancer. METHODS: We identified the incidence of K-RAS mutation in 11 patients of cololectal cancer brain metastasis (CCBM), the incidence of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation in 75 patients of lung cancer brain metastasis (LCBM) and molecular subtype of 33 patients of breast cancer brain metastasis (BCBM) at Seoul St. Mary's hospital between 2012 to 2016. Results: The 50% of CCBM showed K-RAS mutation. The incidence of EGFR mutation and ALK translocation in LCBM were 34% and 16%, respectively. The proportions of luminal-A, luminal-B, Her-2 and triple negative subtypes of BCBM were 29%, 19%, 32% and 19%. The incidence of K-RAS mutation was higher (p=0.010) than primary colorectal cancer (32%). The incidence of EGFR mutation was equal, and the incidence of ALK translocation was significantly higher (p=0.011) than primary lung cancer (34% and 5%). And the proportions of Her-2 subtypes were significantly higher(p=0.000) and luminal-A subtypes was significantly lower (p=0.000) than primary breast cancer (10% and 62%). Conclusions: K-RAS mutation and ALK translocation elevates the metastatic potential of colorectal cancer and lung cancer, respectively. HER2-enriched breast cancer subtypes were associated with a significantly higher rate of brain metastasis. Luminal A subtypes was associated with a significantly lower rate of brain metastasis.